Answers are grounded in this paper and cite their sources.
This article presents the results of the second interim analysis of data from the ValerEE study. The analysis examined a population of patients with advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer receiving either ribociclib combined with endocrine therapy (ET) or combination chemotherapy (CT) as first-line treatment in a real-world clinical setting in Russia. The study enrolled 100 % of the planned number of participants (N=333; 188 in the ribociclib plus ET group and 145 in the combination CT group). The groups were balanced regarding age (mean: 59.2 years), body mass index (mean: 27.7), menopausal status (75.7 % postmenopausal), and gender. Statistically significant differences between the groups were identified: the ribociclib plus ET group showed a higher proportion of patients with an ECOG performance status of 0 (20.7 % vs. 9.7 %, p=0.0208) and higher mean expression levels of estrogen receptors (7.4 vs. 6.9, p<0.001) and progesterone receptors (6.2 vs. 4.9, p<0.001); HER2-low status was also more frequent (38.8 % vs. 31.1 %, p=0.0344). Metastatic disease, including locoregional metastases, was more common in the chemotherapy group. The findings indicate that, in standard clinical practice in the Russian Federation, the selection of patients with HR+/HER2- recurrent/metastatic breast cancer for first-line therapy is based on clinical and biological characteristics. These differences must be taken into account when interpreting the comparative efficacy of these approaches.
No takes yet. Share an insight, caveat, or question.
Zhukova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: